78
Participants
Start Date
August 25, 2025
Primary Completion Date
January 31, 2027
Study Completion Date
May 31, 2027
IDOV-Immune (oncolytic vaccinia virus)
IDOV-Immune is a genetically engineered oncolytic vaccinia virus designed to selectively infect and destroy tumor cells while stimulating the immune system. This study investigates IDOV-Immune as a single intravenous infusion in a first-in-human, Phase 1, dose-escalation trial in participants with advanced solid tumors. The dose will escalate based on safety data, with a goal of identifying the recommended Phase 2 dose (RP2D).
NOT_YET_RECRUITING
Royal North Shore Hospital, Saint Leonards
NOT_YET_RECRUITING
Westmead Hospital, Westmead
RECRUITING
The Alfred Hospital, Melbourne
NOT_YET_RECRUITING
Washington University School of Medicine, St Louis
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
South Texas Accelerated Research Therapeutics, San Antonio
ViroMissile, Inc.
INDUSTRY